Literature DB >> 25384509

Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms.

Anne-Laure Trépant1, Christelle Bouchart, Sandrine Rorive, Sébastien Sauvage, Christine Decaestecker, Pieter Demetter, Isabelle Salmon.   

Abstract

Despite advances in surgical and adjuvant treatments, overall survival of glioblastoma (GBM) patients remains poor. The cancer stem cell concept suggests that a rare stem cell population, called glioma stem cells (GSCs), has high ability to self-renewal leading to recurrence in GBM. The identification of specific markers of GSCs would provide a powerful tool to detect and to characterise them in order to develop targeted therapies. We carried out a comparative analysis based on the identification of inter-study concordances to identify the genes that exhibit at best differential levels of expression between GSC-enriched cell cultures and differentiated tumour cell cultures from independent studies using DNA chip microarray technologies. We finally studied the protein expression of the marker we considered the most specific by immunohistochemistry and semi-quantitative analysis on a retrospective series of 18 GBMs. Of the selected studies, 32 genes were retained. Among them, eight genes were identified to be overexpressed in GSC-enriched cultures compared to differentiated tumour cell cultures. Finally, among the eight genes, oligodendrocyte lineage transcription factor 2 (OLIG2) was characterised by the most different expression level in the "GSC model" compared to the "differentiated tumour cells model". Our approach suggests that OLIG2 is the most specific GSC marker; additional investigations with careful considerations about methodology and strategies of validation are, however, mandatory.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25384509     DOI: 10.1007/s13277-014-2800-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  95 in total

Review 1.  Comparison and meta-analysis of microarray data: from the bench to the computer desk.

Authors:  Yves Moreau; Stein Aerts; Bart De Moor; Bart De Strooper; Michal Dabrowski
Journal:  Trends Genet       Date:  2003-10       Impact factor: 11.639

Review 2.  The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research.

Authors:  Feng Wan; Suojun Zhang; Ruifan Xie; Baocheng Gao; Benito Campos; Christel Herold-Mende; Ting Lei
Journal:  Brain Pathol       Date:  2010-02-05       Impact factor: 6.508

3.  Targeting cancer stem cells through L1CAM suppresses glioma growth.

Authors:  Shideng Bao; Qiulian Wu; Zhizhong Li; Sith Sathornsumetee; Hui Wang; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

4.  The differential expression of Galectin-1 and Galectin-3 in normal lymphoid tissue and non-Hodgkin's and Hodgkin's lymphomas.

Authors:  N D'Haene; C Maris; F Sandras; M-F Dehou; M Remmelink; C Decaestecker; I Salmon
Journal:  Int J Immunopathol Pharmacol       Date:  2005 Jul-Sep       Impact factor: 3.219

5.  The basic helix-loop-helix factor olig2 is essential for the development of motoneuron and oligodendrocyte lineages.

Authors:  Hirohide Takebayashi; Yoko Nabeshima; Shosei Yoshida; Osamu Chisaka; Kazuhiro Ikenaka; Yo-ichi Nabeshima
Journal:  Curr Biol       Date:  2002-07-09       Impact factor: 10.834

6.  Oct4 is expressed in human gliomas and promotes colony formation in glioma cells.

Authors:  Zhanhui Du; Deyong Jia; Shangming Liu; Fuwu Wang; Gang Li; Yanmin Zhang; Xinmin Cao; Eng-Ang Ling; Aijun Hao
Journal:  Glia       Date:  2009-05       Impact factor: 7.452

7.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 9.  Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors:  Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

10.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  20 in total

1.  Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.

Authors:  Sandipan Datta; Thomas Sears; Gino Cortopassi; Kevin Woolard; James M Angelastro
Journal:  Biomed Pharmacother       Date:  2020-12-08       Impact factor: 6.529

Review 2.  Machine learning approaches to study glioblastoma: A review of the last decade of applications.

Authors:  Jessica Valdebenito; Felipe Medina
Journal:  Cancer Rep (Hoboken)       Date:  2019-12

Review 3.  Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects.

Authors:  Anoop K Yadav; Neetin S Desai
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

Review 4.  Molecular markers in glioma.

Authors:  Kirsten Ludwig; Harley I Kornblum
Journal:  J Neurooncol       Date:  2017-02-23       Impact factor: 4.130

5.  Systemic AAV9-IFNβ gene delivery treats highly invasive glioblastoma.

Authors:  Dwijit GuhaSarkar; Qin Su; Guangping Gao; Miguel Sena-Esteves
Journal:  Neuro Oncol       Date:  2016-05-18       Impact factor: 12.300

6.  Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures.

Authors:  Felipe J Núñez; Flor M Mendez; Maria B Garcia-Fabiani; Joaquín Pardo; Marta Edwards; Pedro R Lowenstein; Maria G Castro
Journal:  J Vis Exp       Date:  2019-01-09       Impact factor: 1.355

7.  Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma.

Authors:  Inês M Tenente; Madeline N Hayes; Myron S Ignatius; Karin McCarthy; Marielle Yohe; Sivasish Sindiri; Berkley Gryder; Mariana L Oliveira; Ashwin Ramakrishnan; Qin Tang; Eleanor Y Chen; G Petur Nielsen; Javed Khan; David M Langenau
Journal:  Elife       Date:  2017-01-12       Impact factor: 8.140

8.  Carnosol controls the human glioblastoma stemness features through the epithelial-mesenchymal transition modulation and the induction of cancer stem cell apoptosis.

Authors:  Chiara Giacomelli; Simona Daniele; Letizia Natali; Caterina Iofrida; Guido Flamini; Alessandra Braca; M Letizia Trincavelli; Claudia Martini
Journal:  Sci Rep       Date:  2017-11-09       Impact factor: 4.379

9.  P4HA2 promotes cell proliferation and migration in glioblastoma.

Authors:  Yuying Wu; Xunrui Zhang; Jue Wang; Ruijie Ji; Lei Zhang; Jianbing Qin; Meiling Tian; Guohua Jin; Xinhua Zhang
Journal:  Oncol Lett       Date:  2021-06-10       Impact factor: 2.967

Review 10.  Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds.

Authors:  Ming Hong; Hor Yue Tan; Sha Li; Fan Cheung; Ning Wang; Tadashi Nagamatsu; Yibin Feng
Journal:  Int J Mol Sci       Date:  2016-06-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.